GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » 3-Year FCF Growth Rate

EV Biologics (EV Biologics) 3-Year FCF Growth Rate : 0.00% (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics 3-Year FCF Growth Rate?

EV Biologics's Free Cash Flow per Share for the three months ended in Dec. 2017 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Competitive Comparison of EV Biologics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, EV Biologics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where EV Biologics's 3-Year FCF Growth Rate falls into.



EV Biologics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


EV Biologics  (OTCPK:YECO) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


EV Biologics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of EV Biologics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Updates on FINRA Filings

By ACCESSWIRE ACCESSWIRE 03-09-2022

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021